Literature DB >> 2416520

Symptomatic cimetidine treatment of duodenal and prepyloric ulcers.

S Gustavsson, H O Adami, L Lööf, A Nyberg, O Nyrén.   

Abstract

In a randomized trial, 75 patients with an endoscopically confirmed and symptomatic duodenal (N = 50) or prepyloric (N = 25) ulcer were allocated to cimetidine treatment (1 g/day) either regularly for four weeks (standard treatment group) or regularly for a minimum of one week and thereafter only until the symptoms were controlled (symptomatic treatment group). The four-week healing frequencies in the standard and symptomatic treatment groups were 72 and 67%, respectively. The difference +/- 95% confidence limits was 5 +/- 21%. Prospective recording of pain revealed that the two treatment regimens were about equally effective in relieving symptoms during weeks 2-4. Patients with unhealed ulcers reported pain during the day and night significantly more often than those with healed ulcers. In the symptomatic treatment group the average patient saved 11 days of cimetidine medication during weeks 2-4. We believe that disappearance of symptoms might be a valuable means of deciding when treatment for peptic ulcers can be discontinued. Provided its efficacy and safety can be further confirmed, symptomatic treatment might become a practical and possibly a money-saving mode of ulcer management, which should also be applicable to the ulcer regimens of tomorrow.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416520     DOI: 10.1007/bf01347901

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Controlled trial of cimetidine for symptomatic treatment of duodenal ulcers.

Authors:  P Lance; B G Gazzard
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-19

2.  Controlled trial of cimetidine for symptomatic treatment of duodenal ulcers.

Authors:  A C Flind; J Beresford
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-16

3.  Treatment of active prepyloric and duodenal ulcers with antacid/anticholinergic, cimetidine and placebo.

Authors:  R Gotthard; M Ström; G Bodemar; A Walan
Journal:  Scand J Gastroenterol Suppl       Date:  1982

4.  Peptic ulcer.

Authors:  J I Isenberg
Journal:  Dis Mon       Date:  1981-12       Impact factor: 3.800

5.  Cimetidine or propantheline combined with antacid therapy for short-term treatment of duodenal ulcer.

Authors:  H O Adami; O Björklund; L K Enander; S Gustavsson; L Lööf; A Nordahl; A Rosén
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

6.  Pirenzepine versus cimetidine in duodenal ulcer. A double-blind, placebo-controlled, short-term clinical trial.

Authors:  G Bianchi Porro; P R Dal Monte; M Petrillo; G G Piccari; N D'Imperio; S Daniotti
Journal:  Digestion       Date:  1982       Impact factor: 3.216

7.  Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine.

Authors:  R Gugler; H G Rohner; P Kratochvil; G Brandstätter; H Schmitz
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

8.  Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

Authors:  S Gustavsson; H O Adami; L Lööf; A Nyberg; O Nyrén
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

9.  Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate?

Authors:  K D Bardhan; D S Cole; B W Hawkins; C R Franks
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-27

10.  Maintenance treatment of recurrent peptic ulcer by cimetidine.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

  10 in total
  3 in total

1.  Pyloric and prepyloric ulcers.

Authors:  C Muller; D Liebermann-Meffert; M Allgöwer
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

2.  Cimetidine and ulcers.

Authors:  M P Lance
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

3.  Gastric adenocarcinoma masquerading endoscopically as benign gastric ulcer. A five-year experience.

Authors:  I Podolsky; P R Storms; C T Richardson; W L Peterson; J S Fordtran
Journal:  Dig Dis Sci       Date:  1988-09       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.